There may be 2 or more immune mechanisms in patients with GFAP-A overlap syndrome, and there is no further difference in clinical symptoms between patients with overlap syndrome and those without overlap syndrome, except for the age of onset[12]; however, research has found that patients with overlapping antibodies have a poor response to immunotherapy, poor prognosis, and are more likely to relapse. This evidence concerns the gene GFAP and overlapping connective tissue disease.